Search

Your search keyword '"Marcis Leja"' showing total 235 results

Search Constraints

Start Over You searched for: Author "Marcis Leja" Remove constraint Author: "Marcis Leja"
235 results on '"Marcis Leja"'

Search Results

1. Identification of Volatile Markers of Colorectal Cancer from Tumor Tissues Using Volatilomic Approach

2. Taxonomy-based data representation for data mining: an example of the magnitude of risk associated with H. pylori infection

4. Volatile Markers for Cancer in Exhaled Breath—Could They Be the Signature of the Gut Microbiota?

5. The Role of an Artificial Intelligence Method of Improving the Diagnosis of Neoplasms by Colonoscopy

6. PVAmpliconFinder: a workflow for the identification of human papillomaviruses from high-throughput amplicon sequencing

7. Identification of Key Volatile Organic Compounds Released by Gastric Tissues as Potential Non-Invasive Biomarkers for Gastric Cancer

8. The Influence of Mechanical Bowel Preparation on Volatile Organic Compounds for the Detection of Gastrointestinal Disease—A Systematic Review

9. Profiles of Volatile Biomarkers Detect Tuberculosis from Skin

10. Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment—Results from the GISTAR Pilot Study

11. Volatilomic Signatures of AGS and SNU-1 Gastric Cancer Cell Lines

12. Nanosheets Based Approach to Elevate the Proliferative and Differentiation Efficacy of Human Wharton’s Jelly Mesenchymal Stem Cells

13. Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study

14. The Volatilomic Footprints of Human HGC-27 and CLS-145 Gastric Cancer Cell Lines

15. Modular Point-of-Care Breath Analyzer and Shape Taxonomy-Based Machine Learning for Gastric Cancer Detection

16. Sex differences in the relationship among alcohol, smoking, and infection in asymptomatic individuals

17. Regional variations in Helicobacter pylori infection, gastric atrophy and gastric cancer risk: The ENIGMA study in Chile.

18. Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection?

19. The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

20. Modular Breath Analyzer (MBA): Introduction of a Breath Analyzer Platform Based on an Innovative and Unique, Modular eNose Concept for Breath Diagnostics and Utilization of Calibration Transfer Methods in Breath Analysis Studies

21. miR-20b and miR-451a Are Involved in Gastric Carcinogenesis through the PI3K/AKT/mTOR Signaling Pathway: Data from Gastric Cancer Patients, Cell Lines and Ins-Gas Mouse Model

22. Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy

23. Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer.

30. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management

31. Geographic Variability of Gastric Cancer Incidence in Kazakhstan

32. Toll-Like Receptor 1 Locus Re-examined in a Genome-Wide Association Study Update on Anti–Helicobacter pylori IgG Titers

33. Patients-centered SurvivorShIp care plan after Cancer treatments based on Big Data and Artificial Intelligence technologies (PERSIST): a multicenter study protocol to evaluate efficacy of digital tools supporting cancer survivors.

34. Increased DNA content in stomach fluids: diagnostic implications of a possible new gastric cancer marker

35. Atrophic gastritis and gastric cancer tissue miRNome analysis reveal hsa-miR-129-1 and hsa-miR-196a as potential early diagnostic biomarkers

36. Identifying the Profile of Helicobacter pylori–Negative Gastric Cancers: A Case-Only Analysis within the Stomach Cancer Pooling (StoP) Project

37. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

39. Development and use of an ESBL coding gene panel in patients undergoing first-line eradication therapy for Helicobacter pylori

40. Empirical rescue treatment of

41. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma

42. 129 - EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI EN FUNCIÓN DE LAS RESISTENCIAS ANTIBIÓTICAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

43. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

44. Prevalence and Potential Risk Factors of Helicobacter pylori Infection among Asymptomatic Individuals in Kazakhstan

45. Management of

46. Lifestyle and dietary factors associated with serologically detected gastric atrophy in a Caucasian population in the GISTAR study

47. Sociodemographic, Lifestyle and Medical Factors Associated with Helicobacter Pylori Infection

48. TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors

49. Digestive cancer screening across Europe

50. Prevalence of Atrophic Gastritis in Kazakhstan and the Accuracy of Pepsinogen Tests to Detect Gastric Mucosal Atrophy

Catalog

Books, media, physical & digital resources